Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

AUTHOR

OTS

DATE

January 31, 2020

CATEGORIES

Ago/siRNA/saRNA,Hot Papers,Pre-Clinical Research,Toxicology

Post Views: 371

Sutherland JE, Hettinger JL, Chan A, Gilbert J, Warner GL, Davis WP.

Nucleic Acid Ther. 2019 Dec 10.

PubMed

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
April 23rd, 2021|0 Comments
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
April 23rd, 2021|0 Comments
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics
March 15th, 2021|0 Comments
Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates
March 15th, 2021|0 Comments
Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH
March 15th, 2021|0 Comments
Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology
February 16th, 2021|0 Comments

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

Related articles

Subscribe to our Newsletter

Resources

Stay Connected

Search

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

Subscribe to our Newsletter

Resources

Stay Connected

Search

Login to your account

Reset Password

Signup to your Account

Answers

Job Alerts

Account Activation